Malignant target cells engaged via cytotoxic T lymphocyte mechanisms

Malignant target cells engaged via cytotoxic T lymphocyte (CTL) mechanisms refers to the process where effector CD8+ T cells recognize and eliminate cancerous cells. This interaction is primarily mediated by the T-cell receptor (TCR) recognizing specific tumor antigens presented on Major Histocompatibility Complex (MHC) class I molecules (Janeway et al., 2001, NCBI Bookshelf). Upon successful engagement, CTLs induce apoptosis through the directed release of perforin and granzymes or via death receptor signaling such as Fas/FasL (Voskoboinik et al., 2015, Nature Reviews Immunology). Therapeutic strategies like bispecific T-cell engagers (BiTEs) and CAR-T cells are designed to artificially facilitate this engagement, bypassing natural MHC restrictions to enhance anti-tumor immunity (Labrijn et al., 2019, Nature Reviews Drug Discovery). While potent, the efficacy of this mechanism can be limited by the tumor microenvironment's immunosuppressive signals and the risk of systemic inflammatory responses like Cytokine Release Syndrome (Shimabukuro-Vornhagen et al., 2018, Journal for ImmunoTherapy of Cancer).

Other names

CTL-mediated cytotoxicityT-cell mediated tumor cell killingCytotoxic T-cell engagementCTL-mediated lysis

Induction of direct cell lysis and apoptosis in malignant cells through the recruitment and activation of cytotoxic T lymphocytes (CTLs), typically involving the release of perforin and granzymes or activation of the Fas/FasL pathway (Voskoboinik et al., 2015, Nature Reviews Immunology).